Loading page
Loading page
Loading substance route
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
There is considerable risk of physical harm when taking these combinations, they should be avoided where possible.
These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
Oxymorphone is considered extremely addictive with high abuse potential. Compulsive redosing is commonly reported, and the drug has been classified as a high-risk opioid due to misuse and abuse concerns.
Chronic use reliably produces physical dependence with withdrawal symptoms occurring upon cessation. Neonatal withdrawal syndrome can occur in infants born to mothers who used oxymorphone during pregnancy.
Overdose is characterized by respiratory depression progressing to apnea, circulatory collapse, cardiac arrest, and death. The risk of fatal overdose rises sharply after a period of cessation and relapse due to reduced tolerance.
| Species | Route | Value |
|---|---|---|
| mouse | IV | 172 mg/kg |
Heavy doses can cause respiratory depression leading to dangerous or fatal levels of oxygen deprivation; this is the primary mechanism of opioid overdose death and risk increases substantially when combined with other depressants.
Constipation occurs commonly with use and tolerance to this effect develops particularly slowly compared to other opioid effects.
Severe overdose may cause bradycardia, hypotension, circulatory collapse, and cardiac arrest.
Intravenous injection of the reformulated oral tablet has been associated with a rare TTP-like syndrome (thrombotic microangiopathy); this appears specific to abuse of the crush-resistant formulation and does not occur with intended routes of administration.
Oxymorphone was first developed in Germany in 1914 as part of efforts to create opioid analgesics with improved side effect profiles compared to morphine and heroin. The compound exhibits actions and uses similar to morphine, though notably lacks cough suppressant activity.…
Controlled under the Betäubungsmittelgesetz (Narcotics Act). Manufacturing, importing, possessing, selling, or transferring without a license is prohibited. Anlage II classification permits restricted medical use under appropriate authorization.
Listed under Verzeichnis A in the Swiss controlled substances regulations. Medicinal use is permitted with appropriate authorization and licensing.
Controlled under the Controlled Substances Act. Illegal to sell without a DEA license and illegal to buy or possess without a license or prescription. In 2017, the FDA requested Endo Pharmaceuticals to remove the extended-release formulation from the market due to concerns about opioid misuse and abuse associated with the injectable reformulation.
Classified as a Schedule I controlled substance under Russian drug control legislation. Possession, distribution, and manufacturing without authorization are prohibited.
Controlled under the Misuse of Drugs Act 1971. As a Class A substance, it carries the most severe penalties for unauthorized possession, sale, or distribution. Schedule 2 designation permits medical use under strict controls.
11 sources cited